Low castes have poor access to visceral leishmaniasis treatment in Bihar, India by Pascual Martínez, F et al.
Low castes have poor access to visceral leishmaniasis treatment
in Bihar, India
F. Pascual Martı ´nez
1, A. Picado
2,3, P. Roddy
1 and P. Palma
1
1 Me ´decins Sans Frontie `res – Operational Center Barcelona-Athens, Barcelona, Spain
2 Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
3 Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK
Abstract objectives Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases
in the country. A large proportion of the poor rural communities where VL is endemic are marginalized
by their socio-economic status, intrinsically related to the caste system. In this study, we evaluated
whether people from low socio-economic strata had difﬁculties accessing VL treatment in Bihar. As a
secondary outcome, we evaluated whether people delaying their VL treatment had poorer clinical
indicators at admission.
methods Data on 2187 patients with VL treated by Me ´decins Sans Frontie `res (MSF) in Vaishali
district from July 2007 to December 2008 were analysed. Patients who reported having onset of
symptoms ‡8 weeks before admission were deﬁned as ‘late presenters’. Logistic regression models were
used to evaluate whether low castes had higher risk to be ‘late presenters’ compared to the rest of castes
and whether ‘late presenters’ had poorer indicators at admission (i.e. haemoglobin level, spleen size).
results After adjusting for age, gender and distance to VL treatment facility, Mushars (the lowest
caste in Bihar) had twice the odds to be ‘late presenters’ compared to the rest of castes (OR 2.05, 95%
CI: 1.24–2.38). Subjects that had VL symptoms for ‡8 weeks had a larger spleen and lower haemoglobin
level than those that were treated earlier.
conclusion Low castes have poor access to VL treatment in Bihar, and late presenters have poorer
clinical indicators at admission. These ﬁndings have implications at individual and community levels and
should stimulate targeted VL control programmes to ensure that marginalized communities in Bihar
are properly treated.
keywords Kala azar, visceral leishmaniasis, caste, Bihar, Mushar
Introduction
Visceralleishmaniasis(VL;kalaazar)isadiseasecausedbya
systemic infection of parasites of the genus Leishmania
transmitted to humans via phlebotomine sandﬂies (Hey-
mann 2008). The annual burden of VL is estimated to be
500 000 new cases and 51 000 deaths (WHO, 2004).
Approximately half of VL cases globally occur in India,
where165millionpeopleresidingin52VL-endemicdistricts
are at risk of infection (Desjeux 2004) (India.,
M.o.H.a.F.W.G.o, 2009). Bihar is the most affected state
accountingformorethan90%ofIndia’scases(Ranjanet al.
2005)withanannualincidencerateof22.3casesper10 000
people (Mondal et al. 2009). Bihar’s Vaishali district is
endemicforVLwithanestimatedincidenceof29.8casesper
10 000 per year (S. J. Seena, J. F. Saint Sauveur, P. K. Sinha,
M. C. Vin ˜oles, R. K. Topno, P. Das, P. Roddy, L. Flevaud,
M. A. Lima, P. P. Palma, unpublished data).
In India, VL is caused by Leishmania donovani trans-
mitted by Phlebotomus argentipes (Dedet 2008) in an
anthroponotic cycle (Desjeux 2004). Current VL control
measures are based mainly on indoor residual spraying
(IRS) of households with dichlorodiphenyltrichloroethane
(DDT) and early diagnosis and treatment for those
infected. To date, these measures have been insufﬁcient to
control the disease (Ostyn et al. 2008). A series of available
new tools, namely rapid diagnostic tests and therapeutics
such as liposomal amphotericin B, should facilitate the
implementation of a more effective control strategy for
high VL risk communities. The active detection of and
treatment for VL cases should be an indispensable control
programme component (Mondal et al. 2009). However,
this strategy requires accessing VL-affected communities,
which tend to be marginalized, extremely poor (Boelaert
et al. 2009) and lack access to both diagnosis and
treatment. In India, marginalized communities typically
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2009).
Caste, as a proxy for socio-economic status (Van de Poel
& Speybroeck 2009), is an important determinant of
social position and affects numerous aspects of daily life,
including access to public health services (Babu et al.
2001). The lower strata in the caste system may have
difﬁculties accessing health facilities, not only for ﬁnancial
reasons but also because of social segregation (Alvar et al.
2006). This may reduce awareness and expectations of
treatment and discourage or delay presentation to a health
facility in the event of disease. Delayed treatment for VL
has consequences at community level as infectious cases
help maintaining the transmission cycle of the disease.
Similarly, delayed treatment may be related to poor clinical
parameters at admission (Collin et al. 2004), which may
adversely affect the clinical outcome.
In India, castes and sub-castes are categorized into three
groups:(i)scheduledcastesandtribes(SC⁄T),whichinclude
the former ‘untouchables’ (or ‘Dalit’), the lowest castes; (ii)
other backward classes (OBC); and (iii) other castes (OC),
which include those groups higher in the socio-economic
scale.Inruralcommunitiesinparticular,thecastesystemhas
a rigid hierarchical structure. Mushars are the lowest caste
among the SC⁄T in Bihar (A. Juan, P. Duch, unpublished
report)withanaveragedailyincomeof50Indianrupees(1.1
USD) and poor literacy rates: 2% among males and 0.9%
among females compared with 59.7% and 33.1%, respec-
tively, for the entire state of Bihar (India., G.o, 2001).
Moreover, Mushars report suffering from acts of violence
(Watch 2007). In Bihar, Mushars comprise approximately
2.5% of the total population (India., G.o, 2001).
The primary objective of this study was to determine
whether low castes, and Mushars in particular, had poorer
access to VL treatment in Vaishali district (Bihar) com-
pared to other castes. The secondary study objective was to
determine whether patients with VL who delayed their
treatment had poor clinical indicators at admission.
Materials and methods
Study population
Our study population included patients with VL treated by
Me ´decins Sans Frontie `res (MSF) at Hajipur Hospital in
Vaishali district (Bihar) from July 2007 to January 2009.
Patients with VL symptoms who self-presented to the
hospital’s outpatient department (OPD) or who were
referred to the hospital from one of the Primary Health
Centres (PHC) in the district or from the Rajendra
Memorial Research Institute of Medical Sciences in Patna
(RMRI) were included in the study. Patients with VL
identiﬁed at MSF mobile clinics, thus by active case
detection campaigns, were not included in the analyses. No
transportation fees were paid for the ﬁrst visit. Patients
with VL who completed their VL treatment received an
insecticide-treated net.
Visceral leishmaniasis-suspected patients were conﬁrmed
by a positive rK39 rapid diagnostic test (DiaMed-IT-
Leish
 ; DiaMed) or by demonstration of the parasite in the
spleen or bone marrow aspirates. All patients with VL were
treated with liposomal amphotericin B (Ambisome
 ;
Gilead Sciences), given according to the current World
Health Organization (WHO) recommendation (WHO,
2005a): a total dose of 20 mg⁄kg administered intrave-
nously at 5-mg⁄kg doses on days 0, 1, 4 and 9. An
extended schedule with liposomal amphotericin B was used
as second-line treatment. MSF provided free diagnosis and
treatment. Only VL-conﬁrmed individuals living in Vais-
hali district and treated at Hajipur Hospital were included
in this study (Figure 1).
Study variables
For each patient, demographics (i.e. age in years at
admission, gender, sub-district of residence and caste),
clinical data (i.e. spleen size, nutritional status and
haemoglobin levels), date of onset of symptoms and
co-infections at admission were recorded.
Castes were categorized following the 2001 census
designation (India., G.o, 2001) as SC⁄T, OBC and OC in
ascending social order. Mushars, the lowest caste in Bihar
included in the SC⁄T group, were also identiﬁed and
compared to the rest of castes.
The primary outcome was the number of weeks between
the onset of VL symptoms and presentation to the
treatment site. This variable was divided into quintiles.
Patients in the last quintile, that is, patients who reported
onset of symptoms ‡8 weeks before admission, were
deﬁned as ‘late presenters’.
Clinical variables were deﬁned as follows. Patients’
spleen size and haemoglobin levels were divided into
quintiles per age group: 6 months to 4 years, 5–18 years
and older than 18 years for spleen size; and 6 months to
5 years, 6–11 years, 12–14 years, pregnant women of
any age, non-pregnant women over 15 years and men
over 15 years for haemoglobin levels. Patients whose
spleen size was in the 5th quintile were considered to
have a very large spleen. Similarly, patients whose
haemoglobin level was in the 1st quintile were consid-
ered to have a very low haemoglobin level. Poor
nutritional status was deﬁned according to WHO stan-
dards and included patients that were both severely acute
(below )3z scores of the median WHO growth
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between )3 and )2 z-scores below the median of the
WHO child growth standards) (de Onis et al. 2007;
WHO⁄UNICEF, 2009). Patients suffering from one or
more of HIV, malaria, tuberculosis or pneumonia at
admission were considered as ‘co-infected’.
Other variables considered in the analyses were gen-
der, age at admission and distance to treatment site. Age
was divided into six categories (0.5–5, 6–10, 11–15, 16–
25, 26–35 and >35 years). The distance between the sub-
district of residence and the site of initial admission
(i.e. Hajipur Hospital, PHC or RMRI) was estimated in
Euclidian distance (km) using Google Earth
  and
categorized (0–10, 11–20, 21–30 and 31–40 km).
Statistical analyses
Caste and late presenters. For univariate analyses, the chi-
square and anova tests were used to evaluate baseline
differences among castes divided into three groups (SC⁄T,
OBC and OC) and castes divided into four groups
(Mushars,S C⁄Tw⁄o Mushars, OBC and OC). Unadjusted
analyses were conducted to assess the crude association
between late presenters (outcome) and caste (explanatory
variable) and between late presenters and the following
variables (covariates): gender, distance to treatment site
and age. Unadjusted odds ratios (OR) and their 95%
conﬁdence intervals (CI) were calculated.
For multivariate analyses, a logistic regression model
was used to assess the association between late presenting
patients and caste (comparing Mushar and SC⁄T against
the rest). Gender, distance to the treatment site and age
were included as covariates in the model. The interaction
among variables in the ﬁnal model was checked. Adjusted
OR and their 95% CI were calculated.
Late presenters and clinical parameters. Three multivariate
logistic regression models, one for each clinical parameter
(i.e. haemoglobin level, spleen size and nutritional status),
were used to evaluate whether late presenters had poorer
clinical indicators at admission than patients seeking
treatment earlier (<8 weeks after the onset of VL
symptoms). The models were adjusted for gender, age and
multiple co-infections. Adjusted OR and their 95% CI
were calculated. All analyses were performed using
Stata 11.
Total = 2779
Total = 2187
Excluded
Duplicated records n = 102
Lost to follow up n = 21
Patients living outside Vaishali district
n = 469
Visceral Leishmaniasis (VL) patients treated by Médecins Sans Frontières (MSF)
in Vaishali district (Bihar) from July 2007 to January 2009:
Rajendra Memorial Research Institute of Medical Sciences in Patna (RMRI) n = 343
Rajendra Memorial Research Institute of Medical Sciences in Patna (RMRI) n = 268
Hajipur hospital & Primary Health Centres (PHC) n = 2436
VL patients finally included in the study
Hajipur hospital & Primary Health Centres (PHC) n = 1919
Figure 1 Schematic ﬂow of study partici-
pants. Study participants were selected
among patients with visceral leishmaniasis
(VL) treated by Me ´decins Sans Frontie `res
(MSF) project in Vaishali district from July
2007 to January 2009.
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Ethical approval was obtained from the Indian Ministry of
Health and by the ethical review board at the London
School of Hygiene and Tropical Medicine. All data were
anonymized before the analyses were conducted.
Results
Study population
A total of 2187 patients were enrolled in the study; 74.3%
were admitted at Hajipur Hospital, 13.5% at the PHCs,
and 12.2% were referred from RMRI. 57.2% were boys,
and the study population median age was 16 years (IQR
8.0–32.0). 10.2% of patients were under-ﬁves; 47.7% were
under 15. Nearly a quarter (23.2%) of patients belonged to
SC⁄T; of those, 43.2% were Mushars. The median number
of weeks ill prior to admission was 4 (IQR 3.0–8.0)
(Table 1). 95.7% of patients in the study presented with a
palpable spleen at admission (median cm 5.0 IQR 3.0–8.0).
Patients with spleen size over 8 cm in subjects £18 years
and over 9 cm in subjects >18 years were considered to
have a very large spleen. Haemoglobin levels below 5 g⁄dl
in 0.5- to 5-year-olds or pregnant women, 5.9 g⁄dl in 6- to
11-year-olds, 6.3 g⁄dl in 12- to 14-year-olds, 6.0 g⁄dl in
non-pregnant women over 15 years and 7.2 g⁄dl in men
over 15 years were considered very low. Severe acute
malnutrition was present in 6.6% and moderate malnu-
trition in 11.5% of the population. 3.4% of patients were
diagnosed with one or more co-infections at admission.
The percentage of missing values was low in most of the
variables considered (ranging from 0.1% for age to 1.9%
for multiple co-infections), but relatively high for two
covariates: distance to health centre (21.3%; 467⁄2187)
and nutritional status (22.7%; 496⁄2187). The missing
values in distance to health centre were evenly distributed
among caste groups (P = 0.726 and P = 0.769 for caste
divided into 3 and 4 groups, respectively). However, there
were fewer missing values in the group of late presenters
(15%; 130⁄718) than in the group of people seeking
treatment earlier (20%; 350⁄1794). The difference was
statistically signiﬁcant (P = 0.001).
Statistical analyses
Table 1, which shows baseline characteristics of the caste
groups, reveals that gender was equally distributed in all.
The percentage of males was 57.2 in OC, 57.5 in OBC,
58.1 in SC⁄T without Mushars and 55.1 in Mushars
(P = 0.59). There were no statistically signiﬁcant differ-
ences between castes in distance to treatment site either.
OC, OBC, SC⁄Tw⁄o Mushars and Mushars lived at 24.4,
24.5, 23.7 and 24.5 km from the treatment site, respec-
tively (P = 0.6962). Mushars were younger than the rest.
The mean age was 25.1, 21.8, 21.6 and 19.9 years for OC,
OBC, SC⁄Tw⁄o Mushars and Mushars, respectively
(P = 0.0026).
Caste and late presenters. The median time (in weeks)
between onset of VL symptoms and admission was similar
between SC⁄T, OBC and OC groups (P = 0.099) but
was different between Mushars and the rest of castes
(P = 0.044) (Figure 2). The results of the analyses are
detailed in Table 2. Mushars had more late presenters
(40.9%) than the other castes. In the unadjusted analysis,
Mushars had 1.7 the odds of suffering from VL symptoms
for ‡8 weeks before admission compared to OC
(P = 0.017). When SC⁄T including Mushars were
compared to OC, the OR was reduced to 1.42 and was
not statistically signiﬁcant anymore (P = 0.078). Females
(OR = 1.27 P = 0.01) and subjects over 35 years
Table 1 Characteristics of the study population. Details on the number of study participants per caste group and their characteristics (i.e.
gender, age and distance to treatment site)
Number
(% total)
Num.
males (%)
Age in years –
mean (SD)
Mean distance to
treatment site (km) (SD)
OC 153 (7.0) 87 (57.2) 25.1 (16.6) 24.4 (14.9)
OBC 1456 (67.0) 838 (57.5) 21.8 (16.4) 24.5 (14.0)
SC⁄T( w⁄o Mushars) 320 (14.7) 186 (58.1) 21.6 (15.5) 23.7 (15.4)
Mushars 243 (11.2) 134 (55.1) 19.9 (14.3) 24.5 (12.3)
P-value – 0.5878 <0.0026 0.6962
OC 153 (7.0) 87 (57.2) 25.1 (16.6) 24.4 (14.9)
OBC 1456 (67.0) 838 (57.5) 21.8 (16.4) 24.5 (14.0)
SC⁄T 563 (25.9) 320 (56.8) 20.9 (15.0) 24.1 (14.1)
P-value – 0.9579 <0.0025 0.4867
OBC, other backward classes; OC, other castes; SC⁄T, scheduled castes and tribes.
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Figure 2 Boxplot of time (in weeks) between onset of symptoms and hospital presentation in function of caste. (a) Caste divided into three
groups: scheduled castes and tribes (SC⁄T), other backward classes (OBC) and other castes (OC), and (b) caste divided into four groups:
Mushar, SC excluding Mushar (SC – Mushar), ST and OBC.
Table 2 Crude and adjusted odds ratio (OR) and 95% conﬁdence intervals (CI) for the association between late presenters (patients
with VL symptoms for ‡8 weeks), caste and covariates evaluated by logistic regression. Caste divided into (i) three groups as (a) scheduled
castes and tribes (SC⁄T); (b) other backward classes (OBC); and (c) other castes (OC) in ascending social order and (ii) four groups as
(a) Mushar, (b) SC⁄T without Mushar, (c) OBC and (d) OC
No. of late
presenters
 (%)
Unadjusted
Odds Ratio (95% CI) P-value
Adjusted
Odds Ratio (95% CI) P-value
Caste in 4 groups
OC 44 (28.9) 1 1
OBC 468 (32.4) 1.18 (0.82–1.70) 0.382 1.30 (0.86–2.00) 0.213
Other SC⁄T
 107 (33.4) 1.23 (0.81–1.88) 0.329 1.29 (0.79–2.10) 0.308
Mushars 99 (40.9) 1.70 (1.10–2.62) 0.017 2.05 (1.24–3.38) 0.005
Caste in 3 groups
OC 44 (28.9) 1 1
OBC 468 (32.4) 1.18 (0.82–1.70) 0.382 1.30 (0.85–1.99) 0.219
SC⁄T 206 (36.6) 1.42 (0.96–2.10) 0.078 1.58 (1.01–2.49) 0.045
Sex
Male 383 (31.0) 1
Female 335 (36.3) 1.27 (1.06–1.52) 0.010 1.46 (1.18–1.80) <0.001
Distance (km)
0–10 108 (32.8) 1 1
11–20 205 (34.3) 1.07 (0.80–1.42) 0.642 1.08 (0.80–1.44) 0.618
21–30 149 (36.0) 1.15 (0.85–1.56) 0.368 1.15 (0.84–1.57) 0.384
31–40 101 (28.0) 0.80 (0.57–1.10) 0.167 0.84 (0.60–1.17) 0.309
Age
6 months–5 years 72 (32.1) 1 1
6–10 years 143 (27.5) 0.80 (0.57–1.12) 0.195 0.87 (0.59–1.29) 0.478
11–15 years 72 (25.3) 0.71 (0.48–1.05) 0.088 0.70 (0.45–1.09) 0.115
16–25 years 155 (37.9) 1.29 (0.91–1.82) 0.149 1.33 (0.89–1.99) 0.157
26–35 years 105 (31.1) 0.95 (0.66–1.37) 0.788 1.00 (0.66–1.53) 0.986
>35 years 171 (44.4) 1.69 (1.19–2.38) 0.003 2.03 (1.35–3.04) 0.001
Late presenter deﬁned as patients with visceral leishmaniasis (VL) that had VL symptoms for ‡8 weeks before admission.
SC⁄T excluding Mushar caste.
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presenters than males and children (0.5–5 years),
respectively.
These results were conﬁrmed in the adjusted model
where gender, age and distance were included as covari-
ates. Mushars had twice the odds of being late presenters as
OC (OR 2.05; 95% CI 1.24–3.38). Similarly, when 3 caste
groups were considered, SC⁄T (including Mushar) had
1.58 the odds of delaying their VL treatment compared to
OC (95% CI 1.01–2.49). The risk of being late presenters
in females and subjects over 35 years increased in the
adjusted model (OR = 1.46 and OR = 2.03, respectively).
Distance to treatment centre was not associated with
delayed presentation in the crude or adjusted models
(Table 2). No interactions among variables in the ﬁnal
model were found.
Late presenters and clinical parameters. The results of the
multivariate regression models studying the association
between late presenters and clinical outcomes are
summarized in Table 3. Late presenters had 1.81 the odds
of having a very low haemoglobin level (<5 g⁄dl in 0.5- to
5-year-olds and pregnant women, <5.9 g⁄dl in 6- to
11-year-olds, <6.3 g⁄dl in 12- to 14-year-olds, <6.0 g⁄dl in
non-pregnant women over 15 years and <7.2 g⁄dl in men
over 15 years) and 2.34 the odds of having very large
spleen (>8 cm in those £18 years and >9 cm in those
>18 years) at admission compared to people treated earlier.
Both results were highly statistically signiﬁcant
(P < 0.001). Haemoglobin level was also associated with
multiple co-infections (OR = 3.62, P = 0.013). Late
presenters did not have a poor nutritional status at
admission, but females (OR = 1.41) and individuals over
35 years (OR = 2.02) had a higher risk of being
malnourished than males and under-ﬁves.
Discussion
The main objective of this study was to assess whether
marginalized communities in Bihar had difﬁculties access-
ing VL treatment using caste and delayed presentation to
the treatment as a proxy measures for socio-economic
status and access to health system, respectively. Mushars
(the lowest caste) and SC⁄T (the lowest caste category)
signiﬁcantly delayed their VL treatment compared to OC
(the highest caste category) (OR = 2.05 and 1.58, respec-
tively). These difﬁculties accessing health services could be
related to poverty as low castes are signiﬁcantly poorer and
have worse and more unstable occupations than higher
castes (Thakur 2000). Poor access to treatment may also be
due to social factors associated with low castes such as
poor education, preference for traditional healers or social
exclusion (A. Juan, P. Duch, unpublished report). The fact
that economic data were not gathered in this study
precluded adjusting the risk of delaying VL treatment by
poverty. However, in this study, treatment was provided
free of charge by MSF (Sinha et al. 2010), and the use of
liposomal amphotericin B required fewer days of hospi-
talization than antimonials (Barratt & Legrand 2005).
These elements limited the additional costs associated
with VL treatment, which disproportionately bear on the
poor. Thus, caste, as a social determinant, seems to be a
genuine factor determining the access to treatment, at least
in this study population. Even if this study is limited to
Table 3 Adjusted odds ratio (OR) and 95% conﬁdence intervals (CI) for the association between late presenters (patients with VL
symptoms for ‡8 weeks) and clinical parameters at admission adjusted by covariates (i.e. gender, age and multiple co-infection) assessed by
logistic regression. Clinical parameters analysed: (i) very low haemoglobin level (<5 g⁄dl, <5.9 g⁄dl, <6.3 g⁄dl, <6.0 g⁄dl and <7.2 g⁄dl in
0.5- to 5-years-olds and pregnant women, 6- to 11-year-olds, 12- to 14-year-olds, non-pregnant women over 15 years and men over
15 years, respectively), (ii) very enlarged spleen (>8 cm in subjects £18 years and >9 cm in subjects >18 years) and (iii) poor nutritional
status (deﬁned according to WHO standards malnutrition (de Onis et al. 2007; WHO⁄UNICEF, 2009))
Very low haemoglobin
 Very large spleen
 Poor nutritional status
§
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Late presenters
– 1.81 (1.40–2.35) <0.001 2.34 (1.87–2.94) <0.001 1.13 (0.89–1.44) 0.302
Female 1.14 (0.91–1.43) 0.252 0.86 (0.69–1.08) 0.198 1.41 (1.12–1.78) 0.004
Age older than 35 y 1.02 (0.77–1.37) 0.862 0.87 (0.64–1.17) 0.350 2.02 (1.55–2.63) <0.001
Multiple co–infections
** 3.62 (1.31–10.03) 0.013 1.23 (0.69–2.20) 0.489 1.07 (0.58–1.98) 0.836
Very low haemoglobin deﬁned as (<5 g⁄dl, <5.9 g⁄dl, <6.3 g⁄dl, <6.0 g⁄dl and <7.2 g⁄dl in 0.5- to 5-year-olds and pregnant women,
6- to 11-year-olds, 12- to 14-year-olds, non-pregnant women over 15 years and men over 15 years, respectively)
Very large spleen deﬁned as over 8 cm in subjects £18 years and over 9 cm in subjects >18 years
§Poor nutritional status deﬁned as below )3z scores of the median WHO growth standards
–Late presenters deﬁned as who reported having onset of symptoms ‡8 weeks before admission.
**Multiple co-infections deﬁned as one or more of the following diseases at admission: HIV, malaria, tuberculosis or pneumonia.
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VL-endemic districts in Bihar with a similar socio-eco-
nomic structure.
When caste was taken into account, female and older
(>35 years) patients with VL delayed their treatment
longer than men and children under ﬁve (OR = 1.46 and
OR = 2.03, respectively). Females may have difﬁculties
accessing health services because of social exclusion,
childbearing and rearing and working responsibilities
(WHO, 2009). The occupation responsibilities may also
explain that older people, who tend to provide the most of
the household income, delay their VL treatment.
The results of this study should stimulate speciﬁc
programmes targeting groups that have difﬁculties access-
ing health services in Bihar, especially low castes and
females. In the context of VL control, such programmes
should ensure that those risk groups are diagnosed and
treated properly. Early identiﬁcation and treatment of VL
cases is one of the pillars of the VL elimination initiative in
the Indian subcontinent (WHO, 2005b) as symptomatic
individuals are infectious and contribute to maintaining the
disease in endemic communities.
At individual level, patients with VL delaying their
treatment had worse clinical indicators at admission:
increased anaemia risk (OR = 1.81) and spleen size
(OR = 2.34).InaVLriskfactorstudyinSudan(Collinet al.
2004), these factors were associated with poor prognosis as
well. This study showed that adult patients who had
symptomsfor‡8 weekshadahigherrisktodie(OR = 2.25).
As observed in the current study, this group of patients from
Sudan also had a lower haemoglobin level (OR = 3.98 for
haemoglobin <8 g⁄dl in adults and OR = 3.65 < 6 g⁄dl in
children) and larger spleen size in children (OR = 2.85 for
grade 3 to 5, Hackett spleen classiﬁcation). We did not
evaluatewhetherlatepresenterswereathigherriskofdeath,
because liposomal amphotericin B is very effective and
98.8% were treated successfully (Sinha et al. 2010). How-
ever, poor indicators at admission may be related to poor
prognosis when less effective or more toxic drugs, such as
sodium stibogluconate (SSG), are used (Collin et al. 2004;
Hasker et al. 2010).
Malnutrition has been associated with VL development
(Cerf et al. 1987; Dye & Williams 1993) and risk of death
in patients with VL (Collin et al. 2004). In this study, the
risk of malnutrition was not signiﬁcantly increased in
patients who had been ill for at least 8 weeks (Table 3).
The association with malnutrition may be partially masked
by the unbalanced distribution of missing values in the late
presenters’ variable. Nevertheless, when late presenters
were taken into account in the model, female and older
(>35 years) patients were more likely to suffer malnutrition
than males and children.
The use of caste and reported number of weeks ill as
proxy measures for socio-economic status and access to
health services has limitations (i.e. recall or misclassiﬁca-
tion bias). Similarly, the lack of economic data did not
allow independent evaluation of the effect of caste in the
access to VL treatment in Bihar. Nevertheless, the results of
this study indicate that marginalized communities in Bihar
had difﬁculties accessing health services, even when they
are provided for free. Further research is warranted to
explore the reasons for delaying VL treatment in scheduled
castes and tribes and Mushar in particular in Bihar, as well
as in women. Anthropological studies could help assess the
social determinants of treatment seeking and in the design
of strategies to improve access to VL treatment among
Mushar and women in Bihar. VL control programmes
should consider targeting the risk groups identiﬁed in this
study to ensure that they are treated properly. Active VL
case detection campaigns (i.e. mobile clinics) in endemic
communities could help identifying and treating patients
with VL earlier. This strategy should be accompanied by
educational activities to increase awareness about VL
prevention, diagnosis and treatment in endemic commu-
nities. Reducing the time patients with VL remain infec-
tious will help controlling the transmission of L. donovani
in endemic communities.
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